Dasatinib Induced Avascular Necrosis of Femoral Head in Adult Patient with Chronic Myeloid Leukemia

Mohamed A. Yassin1, Abbas H. Moustafa2, Abdulqadir J. Nashwan3, Ashraf T. Soliman4, Hatim El Derhoubi5, Shehab F. Mohamed1, Deena S. Mudawi1, Sarah ELKourashy1, Deena-Raiza Asaari3, Hope-Love G. Gutierrez3, Radwa M. Hussein5, Mohamed Al Musharraf6, Samah Kohla6, Ahmed Elsayed7 and Nader Al-Dewik8

1National Center for Cancer Care and Research, Department of Hematology and BMT, Hamad Medical Corporation, Doha, Qatar. 2Department of Radiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. 3National Center for Cancer Care and Research, Department of Nursing, Hamad Medical Corporation, Doha, Qatar. 4Department of Pediatrics, University of Alexandria, Doha, Qatar. 5National Center for Cancer Care and Research, Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar. 6Department of Pathology, Al-Azhar University, Cairo, Egypt. 7Orthopedic and Musculoskeletal Oncology, Hamad Medical Corporation, Doha, Qatar. 8Qatar Medical Genetic Center, Hamad Medical Corporation, Doha, Qatar.

ABSTRACT: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia (Ph) chromosome resulting from the reciprocal translocation t(9;22)(q34;q11). The molecular consequence of this translocation is the generation of the BCR–ABL fusion gene, which encodes a constitutively active protein tyrosine kinase. The oncogenic protein tyrosine kinase, which is located in the cytoplasm, is responsible for the leukemia phenotype through the constitutive activation of multiple signaling pathways involved in the cell cycle and in adhesion and apoptosis. Avascular necrosis of the femoral head (AVNFH) is not a specific disease. It occurs as a complication or secondary to various causes. These conditions probably lead to impaired blood supply to the femoral head. The diagnosis of AVNFH is based on clinical findings and is supported by specific radiological manifestations. We reported a case of a 34-year-old Sudanese female with CML who developed AVNFH after receiving dasatinib as a second-line therapy. Though the mechanism by which dasatinib can cause avascular necrosis (AVN) is not clear, it can be postulated because of microcirculatory obstruction of the femoral head. To the best of our knowledge and after extensive literature search, this is the first reported case of AVNFH induced by dasatinib in a patient with CML.

KEYWORDS: dasatinib, CML, avascular necrosis of the femoral head (AVNFH)

Background

Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder with an initially chronic course lasting for 3–5 years. It eventually transforms into accelerated or blastic phases, which are generally fatal. CML was one of the first diseases in which a specific chromosomal abnormality was identified, a t(9;22)(q34;q11) or Philadelphia (Ph) chromosome.

Avascular necrosis of the femoral head (AVNFH) occurs as a complicated traumatic or nontraumatic disorder. Most cases of AVNFH are nontraumatic and occur secondary to excessive corticosteroid use and alcohol abuse.1 Other causes include coagulopathies, hemoglobinopathies (eg, sickle cell disease), chronic liver disease, gout, idiopathic hyperlipidemia, metabolic bone disorders, pregnancy, radiation, chemotherapy, smoking, systemic lupus erythematosus, and vasculitis syndromes. Intravascular coagulation appears to be the central event associated with nontraumatic AVNFH.2 Coagulation may occur secondary to extravascular compression (eg, marrow fat enlargement), vessel wall injury (eg, chemotherapy, radiation), or a thromboembolic event (eg, fat emboli). In addition, ischemic insult to the femoral head may result in subchondral bone infarction. In this situation, weakened and unrepaired necrotic bony trabeculae fail under a compressive load, leading to subchondral collapse (eg, crescent sign), and ultimately, articular collapse.3 Traumatic causes of femoral head avascular necrosis (AVN) include femoral neck fractures, hip dislocation, and slipped capital femoral epiphysis.4 AVNFH can be presenting manifestation for a patient with CML. We did literature review and came with number of cases reporting AVNFH as an initial presentation of CML, illustrated in Table 1.

Case Presentation

A 34-year-old Sudanese female with the diagnosis of CML was started on imatinib as a first-line therapy, but she failed...
She was referred to the hematology service at the National Center for Cancer Care & Research (NCCCR) for further evaluation. Her clinical examination was unremarkable, and her work-up was repeated, including a complete blood count, cytogenetics, and BCR/ABL by PCR. Plain radiograph before treatment was available and she was reported as normal. Her work-up revealed a chronic phase of CML in failing first-line therapy. She was started on dasatinib 100 mg PO once daily as a second-line therapy with which she achieved CHR, CCYR, and MMR at 18 months. After 18 months on therapy with dasatinib, she presented with severe pain in her left groin with limping. Her complete blood count (CBC) was within normal limit—WBC 6000, Hb 13 g/dL, and Plts 235,000. Her peripheral smear reported as normal, and her disease reevaluated at the molecular level and showed major molecular response. Radiological evaluation, including pelvic radiography (see Fig. 1A and B) and magnetic resonance imaging (MRI) showed grade 3–4 AVNFH (see Fig. 2A–E).

She underwent total hip replacement, which was successful.

**Discussion**

AVNFH is a recognized complication for a group of traumatic and nontraumatic disorders. The incidence of AVNFH in CML is not identified. This is because of the limited number of reports and absence of prospective studies evaluating this issue in this situation. In addition, whether the disease itself and/or the treatment encourage the development of AVNFH is not known. Post-contrast material-enhanced MRI with its inherent high spatial resolution capabilities is considered an excellent diagnostic tool for detecting and staging of femoral head AVN. It is considered the preferred method for diagnosis of occult AVN, since it is more sensitive than bone scan or plain films. Owing to the high incidence of bilateral AVN, MRI may pick up AVN in opposite asymptomatic hip. An AVN lesion is typically a well-demarcated epiphyseal area of altered and variable signal intensity (Figs. 1 and 2). In its early stages, T2-weighted

| PATIENT | AGE | GENDER | SITE        | NOTE                                      | YEAR | REFERENCE |
|---------|-----|--------|-------------|-------------------------------------------|------|-----------|
| 1       | 24  | Male   | Rt Femoral Head | Leukocyte count 96,800/mm³, Platelets count 684,000/mm³, and Hemoglobin 10.4 g/dL | 2005 | Moon JY, et al⁶ |
| 2       | 15  | Female | Rt Femoral Head | Leukocyte count of 290 × 10⁹/L, Platelet count 250 × 10⁹/L, Hemoglobin 10.8 g/dL | 2003 | Gupta D, et al⁸ |
| 3       | 17  | Male   | Rt Femoral Head | Unknown                                  | 1984 | Gibson J, et al⁷ |
| 4       | 9   | Female | Lt Femoral Head | Leukocyte count 359,000/mm³, Platelets count 809,000/mm³                         | 1988 | Salimi Z, et al⁸ |
| 5       | 17  | Male   | Rt Femoral Head | Unknown                                  | 1996 | Leone J, et al⁹ |
| 6       | 12  | Female | Rt Femoral Head | Unknown                                  | 2013 | Leone J, et al¹⁰ |

Table 1. CML presenting with AVNFH.

**Figure 1.** (A) Plain radiography (anteroposterior (AP) view of both hip joints) and (B) pelvic radiography (close oblique view of the left hip).**

**Notes:** Plain radiography of the hip joints: AP view and oblique view of the left hip showing heterogeneous matrix of the left femoral head giving geographical appearance with mixed sclerosis and lucent areas as well as relative mild narrowing of the ipsilateral joint space representing AVN-related changes.
Figure 2. MRI of both hip joints: (A) axial view of the T2WI sequence, (B) axial view of the T1WI sequence post-contrast (gadolinium DTPA) intravenous administration, (C) coronal view of the T2WI sequence, (D) coronal T2 STIR sequence, and (E) sagittal view of the left hip joint T2WI sequence.

Notes: MRI examination of the hip joints before and after intravenous administration of gadolinium. Axial, coronal, and sagittal views of the hip joints T1, T2, and STIR showing multiple subarticular areas of abnormal signal intensity within the head left femur, mainly at the superoanterior medial aspect showing low T1 signal intensity and non-homogenous mixed T2-fat suppression with mild enhancement. Associated mild degenerative changes and thickened synovium are noted, consistent with stage III–IV AVN. No signs of AVN on the right hip were detected.
images and STIR short tau-inversion recovery can help in detection of necrotic tissue in some unusual AVN lesions that mostly showed ill-delimited edema-like marrow changes.\textsuperscript{11,12} MRI has 90–100\% sensitivity for symptomatic disease. In some cases, contrast-enhanced MRIs may increase diagnostic confidence by showing homogeneous hypervascularization in bone marrow edema lesions and by depicting hypovascular marrow areas in AVN lesions. Also the MRI can discriminate between the AVN and transient marrow edema.\textsuperscript{11,13} Sequential and follow-up MRI is considered valuable in the assessment of equivocal femoral head lesions, especially in its early stages where the findings are usually trivial.\textsuperscript{12,13}

Treatment historically has passed through two eras. The era of interferon: there is a limited data that interferon alfa 2a can cause AVNFH. There are no reports in the literature about AVNFH with other therapeutic uses of interferon alfa. Therefore, the occurrence of AVNFH in patients with CML on interferon treatment may be the result of an interaction between CML and interferon alfa therapy. Interferon alfa can inhibit angiogenesis, which may cause AVN, and the stress of weight bearing may make the femoral head, particularly, vulnerable.\textsuperscript{14} The second era for CML treatment started with using tyrosine kinase inhibitor (TKI) Table 3. Few cases of AVNFH have been reported at disease presentation (CML) as well as with the use of first-generation TKIs imatinib (Glivec\textsuperscript{®}). Though the mechanism by which dasatinib can cause AVN is not clear, it can be postulated because of microcirculatory obstruction of the femoral head.

Era of Interferon-alfa\textsuperscript{15} AVN in CML patients treated with interferon. Table 2 illustrates that patients with CML developed AVNFH while on interferon alfa.

**Conclusion**

The above mentioned review of literature states that six patients with CML presented with AVNFH as the initial presentation prior to any therapy, five in the era of interferon and two in the era with TKIs, and one with imatinib and the other with dasatinib treatment. There are two issues to be considered: either the condition is rare or there is underreporting of this side effect. Observational studies with proper reporting are required to accurately measure the incidence of this complication, which could significantly affect patients’ safety and quality of life.

**Author Contributions**

Conceived and designed the experiments: MAY. Analyzed the data: MAY, AHM. Wrote the first draft of the manuscript: MAY, AHM. Contributed to the writing of the manuscript: MAY, AHM. Agree with manuscript results and conclusions: MAY, AHM, AJN, ATS, HE, SFM, DSM, SE, DRA, HLGG, RMH, MAM, SK, NAD, AE. Jointly developed the structure and arguments for the paper: MAY, AHM. Made critical revisions and approved final version: MAY, AHM, AJN, ATS, HE, SFM, DSM, SE.
Table 3. Patients treated with TKIs.

| PATIENT (Yrs) | GENDER | INTERVAL FROM CML dx TO DEVELOPMENT OF AVN | PLATELET AND WBC COUNTS AT TIME OF AVN dx | TKI DOSE | OTHER Rx | COMMENT |
|---------------|--------|-------------------------------------------|------------------------------------------|----------|---------|---------|
| 1             | Male   | 8 years                                   | WBC 5600/mm³                              | Start dose 400 mg/d; escalated to 600 mg/d to achieve complete cytogenetic response | Dx as CML (chronic phase in 2005; started on imatinib 400 mg (340 mg/m²) after 20 months dose escalated to 600 mg/day (continued for 1 yr) | DEX 18 months after Gastroin CHR, CCR, MMR |
| 2             | Female | 3 years                                   | WBC 6000, Hb 13 g/dL, and Plts 235/L       | Failed imatinib 400 mg Then shifted to Dasatinib 100 mg | Developed AVNFH |

DRA, HLGG, RMH, MAM, SK, NAD, AE. All authors reviewed and approved of the final manuscript.

REFERENCES

1. Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. *J Bone Joint Surg Am.* 1995;77(3):459–474.

2. Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. *Clin Orthop Relat Res.* 2001;386:173–178.

3. Laveria CJ, Sierra RJ, Grieco FR. Osteonecrosis of the femoral head. *J Am Acad Orthop Surg.* 1999;7(4):250–261.

4. Arlet J, Ficat P. [Non-traumatic avascular femur head necrosis. New methods of examination and new concepts] [Polish]. *Chir Narzadow Ruchu Ortop Pol.* 1977;42(3):269–276.

5. Moon JY, Kim BS, Yun HR, et al. Rheology of leukocytes, leukocyte suspensions, and blood in leukemia possible relationship to clinical manifestations. *Korean J Intern Med.* 2005;20(3):255–259.

6. Gupta D, Gaiha M, Siddaraju N, Daga MK, Anuradha S. Chronic myeloid leukemia presenting with avascular head. *J Assoc Physicians India.* 2003;51:214–215.

7. Gibson J, Joshua DE, Collis D, Kronenberg H. Chronic myeloid leukaemia presenting as femoral head necrosis. *Sand J Haematol.* 1984;32:376–378.

8. Salimi Z, Vas W, Sundaram M. Avascular bone necrosis in an untreated case of chronic myelogenous leukemia. *Skeletal Radiol.* 1988;17:353–355.

9. Leone J, Vilque JP, Pignon B, et al. Avascular necrosis of the femoral head as a complication of chronic myelogenous leukemia. *Skeletal Radiol.* 1996;25:696–698.

10. Kumar S, Bansal D, Prakash M, Sharma P. Avascular necrosis of femoral head as the initial manifestation of CML. *Pediatric Hematol Oncol.* 2014;31(6):568–573.

11. Vande Berg BE, Malghem JJ, Labaisse MA, Noel HM, Maldague BE, Vande Berg BE. MR imaging of avascular necrosis and transient marrow edema of the femoral head. *Radiographics.* 1993;13:501–520.

12. Karantanas AH, Dragoskei EE. The role of MR imaging in avascular necrosis of the femoral head. *Semin Musculoskelet Radiol.* 2011;15(3):281–300.

13. Sanzgiri RK, Neel MD, Soto-Fourier M, Kaste SC. Unique MRI findings as an early predictor of osteonecrosis in pediatric acute lymphoblastic leukemia. *AJR Am J Roentgenol.* 2012;198(5):W432–W439.

14. Smith DW. Is avascular necrosis of the femoral head the result of inhibition of angiogenesis? *Med Hypotheses.* 1997;49(6):497–500.

15. Kozuch P, Talpaz M, Faderl S, O’Brien S, Freireich EJ, Kantarjian H. Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha: a synergistic correlation? *Cancer.* 2000;89(7):1482–1489.

16. Nataraj V, Kandasamy D, Bakhshi S. Imatinib-induced avascular necrosis of femur in childhood chronic myeloid Leukemia. *Pediatr Hematol Oncol.* 2014;31:268–270.

17. Yassin MA. Dasatinib-induced avascular necrosis of femoral head in adult patient with chronic myeloid leukemia. *Clin Med Insights: Blood Disorders.* 2014;8:1447–1459. doi:10.1016/S0140-6736(13)62120-0. Epub 2014 Dec 5.

18. Vaid TP, Covington DB. The incidence of osteonecrosis. In: Urbanik JR, Jones JR, eds. *Osteonecrosis: Etiology, Diagnosis, Treatment.* Rosemont: American Academy of Orthopedic Surgeons; 1997:43–49.